Company: PFSA
Filing Date: 2025-05-13
Form Type: S-4/A
Source: 0001213900-25-042224
Chunk: 506

Company: Profusa, Inc.
Filing Date: 2025-05-13
Form: S-4/A
Chunk 506
---
, he served as the executive vice president and chief financial officer for Questcor Pharmaceuticals which was acquired by Mallinckrodt in a $5.6B transaction. Mr.Asarpota also spent a decade at Life Technologies, a global life sciences company where he was responsible for helping scale the organization, driving growth through organic and M&A channels. During his tenure, the company revenue grew from approximately $1B to more than $4B in 2014, leading to the company’s sale to Thermo Fisher for $13.6 billion that year. Prior to Life Technologies, Mr. Asarpota spent 11 years at GE in several finance leadership roles. Mr. Asarpota holds a M.B.A. from Marquette University and a Bachelor of Commerce from the University of Bombay. We believe that Mr. Asarpota is well -qualifiedto serve as a director of our company based on his healthcare focused experience. Corporate Governance We will structure our corporate governance in a manner NorthView and Profusa believe will closely align our interests with those of our stockholders following the Business Combination. Notable features of this corporate governance include: •we will have a majority of independent directors and independent director representation on our audit, compensation and nominating committees immediately following the consummation of the Business Combination, and our independent directors will meet regularly in executive sessions without the presence of our corporate officers or non -independentdirectors; •at least one of our directors will qualify as an “audit committee financial expert” as defined by the SEC; and •we will implement a range of other corporate governance practices, including implementing a robust director education program.

292 Classification of Board of Directors Following completion of the Business Combination, New Profusa’s board of directors will consist of five members and be divided into three classes of directors that will serve staggered three -yearterms. At each annual meeting of stockholders, a class of directors will be elected for a three -yearterm to succeed the same class whose term is then expiring. As a result, only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three -yearterms. Our directors will be divided among the three classes as follows: •the Class I director will be Lauren Chung, and her terms will expire at the first annual meeting of stockholders to be held after the completion of the Business Combination; •the Class II directors will be Jack Stover and Peter O’Rourke, and their terms will